Investigating the role of a specific microRNA in brain tumors
Official title: Epigenetics and 3D Structure of miR-10b/HoxD Locus in the Brain and Malignant Glioma
Funded at Brigham and Women's Hospital · NIH-10892994 · Data updated 2026-11-12
This study is looking at how a tiny molecule called microRNA-10b affects the growth of glioblastoma, a tough type of brain cancer, to find new ways to help treat patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 15, 2020 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $598,782 |
| NIH project number | 5R01NS113929-05 |
| Project ID | NIH-10892994 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with glioblastoma or other types of malignant gliomas.
✕Less likely to help
Patients with non-malignant brain tumors or those without glioblastoma may not benefit from this research.
What this research studies
This research focuses on glioblastoma, a highly aggressive brain tumor, and explores the role of microRNA-10b in its development and progression. The study aims to understand how this microRNA is activated in gliomas and its impact on tumor growth and survival. By examining the three-dimensional structure of the miR-10b locus in the brain, researchers hope to uncover the epigenetic changes that contribute to glioblastoma. This could lead to new therapeutic strategies targeting miR-10b for treating patients with this challenging cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that target glioblastoma more effectively, potentially improving survival rates for patients.
How similar studies have gone: Previous research has shown promise in targeting microRNAs for cancer treatment, suggesting that this approach could be beneficial.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Krichevsky, Anna M. — Brigham and Women's Hospital
- Study coordinator: Krichevsky, Anna M.
Related research
Other NIH-funded projects on the same topics.
-
Synergistic blood-brain barrier opening and targeted glioma treatment with pulsed electric fields
A new approach uses tiny, rapid electric pulses to safely disrupt the brain's protective barrier and enhance targeted treatment for malignant glioma.
-
Neural stem cells carrying cancer-killing viruses to treat brain cancer
A study tests delivering a virus that specifically targets brain tumors using neural stem cells to reach cancer cells across the brain.
-
Self-assembling camptothecin gel for local brain tumor treatment
A Johns Hopkins-led study is testing a new injectable gel that releases a cancer drug over time to help treat glioblastoma after brain tumor surgery.
-
Inhibiting IDH1 to Trigger Ferroptosis in Aggressive Brain Cancer
Aimed at slowing hard-to-treat brain tumors by blocking a cancer-fueling enzyme (IDH1) in tumors that don’t have a common mutation, potentially making tumors easier to kill with radiation or immune therapies.
-
Neural stem cell delivery of cancer‑killing virus for malignant brain tumors
This work uses neural stem cells to carry cancer‑killing viruses into the brain to treat people with malignant glioma.
-
Camptothecin nanofiber gel placed after brain tumor surgery
This project is building a drug-releasing gel surgeons could place in the cavity after removing a malignant glioma to kill leftover cancer cells and help patients live longer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.